Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.verified

KDNY

Price:

$40.39

Market Cap:

$2.71B

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headq...[Read more]

Industry

Biotechnology

IPO Date

2020-10-06

Stock Exchange

NASDAQ

Ticker

KDNY

The PE Ratio as of July 2024 (TTM) for Chinook Therapeutics, Inc. (KDNY) is -12.47

According to Chinook Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -12.47. This represents a change of 63.25% compared to the average of -7.64 of the last 4 quarters.

Chinook Therapeutics, Inc. (KDNY) Historical PE Ratio (quarterly & annually)

How has KDNY PE Ratio performed in the past?

The mean historical PE Ratio of Chinook Therapeutics, Inc. over the last ten years is -30236.81. The current -12.47 PE Ratio has changed -95.88% with respect to the historical average. Over the past ten years (40 quarters), KDNY's PE Ratio was at its highest in in the September 2015 quarter at 2.66M. The PE Ratio was at its lowest in in the June 2015 quarter at -76017.51.

Quarterly (TTM)
Annual

Average

-30236.81

Median

-5459.46

Minimum

-160427.18

Maximum

-2.56

Chinook Therapeutics, Inc. (KDNY) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Chinook Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 186.98%

Maximum Annual PE Ratio = -2.56

Minimum Annual Increase = -99.95%

Minimum Annual PE Ratio = -160427.18

Quarterly (TTM)
Annual
YearPE RatioChange
2022-9.1424.41%
2021-7.34186.98%
2020-2.56-51.81%
2019-5.31-99.95%
2018-10909.78-63.34%
2017-29759.48-27.01%
2016-40773.72-74.58%

Chinook Therapeutics, Inc. (KDNY) Average PE Ratio

How has KDNY PE Ratio performed in the past?

The current PE Ratio of Chinook Therapeutics, Inc. (KDNY) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-6.35

5-year avg

-2186.82

10-year avg

-30236.81

Chinook Therapeutics, Inc. (KDNY) PE Ratio vs. Peers

How is KDNY’s PE Ratio compared to its peers?

Chinook Therapeutics, Inc.’s PE Ratio is greater than DICE Therapeutics, Inc. (-23.17), less than Pliant Therapeutics, Inc. (-4.36), greater than Crinetics Pharmaceuticals, Inc. (-16.17), greater than Ascendis Pharma A/S (-14.09), less than Ventyx Biosciences, Inc. (-0.82), greater than Nuvalent, Inc. (-34.81), greater than Cerevel Therapeutics Holdings, Inc. (-16.92), less than Travere Therapeutics, Inc. (-4.69), greater than Structure Therapeutics Inc. (-17.82), greater than Avidity Biosciences, Inc. (-17.21), greater than Revolution Medicines, Inc. (-15.69), less than Day One Biopharmaceuticals, Inc. (-6.21), less than SpringWorks Therapeutics, Inc. (-8.21), greater than Arcellx, Inc. (-65.30), greater than Vaxcyte, Inc. (-20.87), less than Viridian Therapeutics, Inc. (-4.05), less than KalVista Pharmaceuticals, Inc. (-5.01), less than Theseus Pharmaceuticals, Inc. (-3.19), less than Kura Oncology, Inc. (-10.46),

Build a custom stock screener for Chinook Therapeutics, Inc. (KDNY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Chinook Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Chinook Therapeutics, Inc. (KDNY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Chinook Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Chinook Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Chinook Therapeutics, Inc. (KDNY)?

What is the highest PE Ratio for Chinook Therapeutics, Inc. (KDNY)?

What is the 3-year average PE Ratio for Chinook Therapeutics, Inc. (KDNY)?

What is the 5-year average PE Ratio for Chinook Therapeutics, Inc. (KDNY)?

How does the current PE Ratio for Chinook Therapeutics, Inc. (KDNY) compare to its historical average?